AU2002232509A1 - Estrone-derivatives having cytoprotective activity - Google Patents

Estrone-derivatives having cytoprotective activity

Info

Publication number
AU2002232509A1
AU2002232509A1 AU2002232509A AU3250902A AU2002232509A1 AU 2002232509 A1 AU2002232509 A1 AU 2002232509A1 AU 2002232509 A AU2002232509 A AU 2002232509A AU 3250902 A AU3250902 A AU 3250902A AU 2002232509 A1 AU2002232509 A1 AU 2002232509A1
Authority
AU
Australia
Prior art keywords
estrone
derivatives
cytoprotective activity
population
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002232509A
Inventor
Douglas F. Covey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU2002232509A1 publication Critical patent/AU2002232509A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention is directed to a process for conferring cytoprotection on a population of cells which comprises administering to that population of cells a compound comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto. In particular, the present invention is directed to such a process wherein the administered compound is phenolic, such as a steriod (e.g., estrogen), and has a non-fused polycyclic, hydrophobic substituent attached to the hydroxy-substituted A-ring thereof.
AU2002232509A 2000-11-03 2001-11-05 Estrone-derivatives having cytoprotective activity Abandoned AU2002232509A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24579100P 2000-11-03 2000-11-03
US60/245,791 2000-11-03
PCT/US2001/046924 WO2002036605A2 (en) 2000-11-03 2001-11-05 Estrone-derivatives having cytoprotective activity

Publications (1)

Publication Number Publication Date
AU2002232509A1 true AU2002232509A1 (en) 2002-05-15

Family

ID=22928089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002232509A Abandoned AU2002232509A1 (en) 2000-11-03 2001-11-05 Estrone-derivatives having cytoprotective activity

Country Status (9)

Country Link
US (3) US6844456B2 (en)
EP (1) EP1330467B1 (en)
JP (1) JP2004518637A (en)
AT (1) ATE361310T1 (en)
AU (1) AU2002232509A1 (en)
CA (1) CA2427817C (en)
DE (1) DE60128251T2 (en)
ES (1) ES2287184T3 (en)
WO (1) WO2002036605A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232509A1 (en) * 2000-11-03 2002-05-15 Washington University Estrone-derivatives having cytoprotective activity
JP2005515992A (en) * 2001-12-05 2005-06-02 ミトコー、インク Use of polycyclic phenolic compounds for the treatment of eye diseases
US20070213310A1 (en) 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
AU2003297739A1 (en) * 2002-12-09 2004-08-30 University Of Florida Prodrugs for use a ophthalmic agents
CA2566373A1 (en) 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
DE102004032674A1 (en) * 2004-07-02 2006-01-26 Schering Ag New 2-substituted Estra-1,3,5 (10) -triene-17-ones as inhibitors of 17β-hydroxysteroid dehydrogenase type 1
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US7906210B2 (en) * 2004-10-27 2011-03-15 Nissei Plastic Industrial Co., Ltd. Fibrous nanocarbon and metal composite and a method of manufacturing the same
US20070161611A1 (en) * 2005-12-01 2007-07-12 Dominique Dugourd Polycyclic phenolic compounds and use in treating viral infections
JP4683021B2 (en) * 2007-08-02 2011-05-11 トヨタ自動車株式会社 Catalyst support for forming fuel cell electrode and method for producing polymer electrolyte fuel cell
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2013056181A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SI2935307T1 (en) 2012-12-18 2018-08-31 Washington University Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
KR102396328B1 (en) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
EP3868382A1 (en) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3488852T3 (en) 2013-08-23 2021-02-01 Sage Therapeutics Inc NEUROACTIVE STEROIDS, COMPOSITIONS AND USES
US9425048B2 (en) * 2013-11-06 2016-08-23 Taiwan Semiconductor Manufacturing Co., Ltd. Mechanisms for semiconductor device structure
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SI3206493T1 (en) 2014-10-16 2020-10-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3206494A4 (en) 2014-10-16 2018-07-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
PL3224269T3 (en) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
SI3250210T1 (en) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016134301A2 (en) 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (en) 2016-07-11 2019-05-15 Sage Therapeutics Inc NEUROACTIVE STEROIDS SUBSTITUTED FOR C17, C20 AND C21 AND THEIR USE PROCEDURES
PE20230244A1 (en) 2019-05-31 2023-02-07 Sage Therapeutics Inc NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1509931A (en) 1966-04-29 1968-01-19 Roussel Uclaf Process for the preparation of optically active ketone compounds and products thereof
US3475885A (en) * 1968-05-02 1969-11-04 Millard F Kline Retainer for purification media for gas from sewer line vents
CA942670A (en) 1969-07-28 1974-02-26 Richard A. Edgren Contraceptive compositions
ZA81348B (en) 1980-01-30 1982-02-24 Akzo Nv Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof,processes for their preparation and pharmaceutical compositions
US4330540A (en) 1981-01-29 1982-05-18 Akzo N.V. Ent-16-amino-17-hydroxy-oestra-1,3,5(10)-trienes and derivatives thereof, and pharmaceutical compositions
DE3263877D1 (en) 1981-07-07 1985-07-04 Akzo Nv Process for the selective reduction of a 14, 17-dioxo-8,4-seco-steroid
US4617298A (en) 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5859001A (en) 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6197833B1 (en) 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US6350739B1 (en) 1999-08-11 2002-02-26 University Of Florida Resarch Foundation, Inc. Methods of prevention and treatment of ischemic damage
DE4338314C1 (en) 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage
DE4338316A1 (en) 1993-11-10 1995-05-11 Jenapharm Gmbh New steroids with radicallyophilic substituents, process for their preparation and medicaments containing these compounds
FR2717690B1 (en) 1994-03-24 1996-04-26 Roussel Uclaf Application of aromatic steroids 3 substituted by an aminoalkoxy substituted for obtaining a medicament for controlling sterility, especially male sterility.
FR2718138B1 (en) 1994-04-01 1996-04-26 Roussel Uclaf New steroids comprising in position 20 an amino-substituted chain, process and intermediates for preparation, application as medicaments and pharmaceutical compositions containing them.
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
DE4429397C2 (en) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds
WO1997003661A1 (en) 1995-07-24 1997-02-06 University Of Florida Research Foundation, Incorporated Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells
ES2217538T3 (en) 1997-01-16 2004-11-01 University Of Florida Research Foundation, Inc. COMPOSITIONS TO IMPROVE THE CITOPROTECTING EFFECTS OF POLYCYCLIC PHENOLIC COMPOUNDS THROUGH SYNERGIC INTERACTION WITH ANTIOXIDANTS.
DE19723794A1 (en) 1997-06-06 1998-12-10 Jenapharm Gmbh Non-estrogenic derivatives of estradiol with antioxidant activity
EP1032397A1 (en) 1997-11-24 2000-09-06 University Of Florida Research Foundation, Inc. Testosterone inhibitors and use for the protection of neurons
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6245756B1 (en) 1998-02-27 2001-06-12 Jenapharm Gmbh & Co. Kg Pharmaceutical preparations for treatment of estrogen deficiency in the central nervous system
DE19917930A1 (en) 1999-04-15 2000-10-19 Schering Ag Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity
US6265147B1 (en) 1999-12-01 2001-07-24 The Board Of Trustees Of The Leland Stanford Junior University Method of screening for neuroprotective agents
AU781845B2 (en) * 2000-03-09 2005-06-16 Ciba Specialty Chemicals Holding Inc. A method of colouring hair using cationic dyes
JP3429726B2 (en) * 2000-04-12 2003-07-22 日本クリニック株式会社 Manufacturing method of oyster meat extract
AU2002232509A1 (en) * 2000-11-03 2002-05-15 Washington University Estrone-derivatives having cytoprotective activity
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
AU2003224816A1 (en) * 2002-04-01 2003-10-20 University Of Florida Steroidal quinols as prodrugs of antioxidants
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
CA2566373A1 (en) * 2004-05-27 2005-12-08 Migenix Corp. 2-substituted 17-imino estrogen compounds for cytoprotection
US20070161611A1 (en) * 2005-12-01 2007-07-12 Dominique Dugourd Polycyclic phenolic compounds and use in treating viral infections

Also Published As

Publication number Publication date
US6844456B2 (en) 2005-01-18
DE60128251D1 (en) 2007-06-14
WO2002036605A2 (en) 2002-05-10
US9156876B2 (en) 2015-10-13
EP1330467A2 (en) 2003-07-30
US20110015165A1 (en) 2011-01-20
ATE361310T1 (en) 2007-05-15
WO2002036605A9 (en) 2002-10-17
ES2287184T3 (en) 2007-12-16
EP1330467B1 (en) 2007-05-02
WO2002036605A3 (en) 2002-07-11
US20060009438A2 (en) 2006-01-12
US20020103178A1 (en) 2002-08-01
US20050054624A1 (en) 2005-03-10
CA2427817C (en) 2009-04-14
DE60128251T2 (en) 2008-01-10
CA2427817A1 (en) 2002-05-10
JP2004518637A (en) 2004-06-24

Similar Documents

Publication Publication Date Title
AU2002232509A1 (en) Estrone-derivatives having cytoprotective activity
AU2610699A (en) Derivatives of glp-1 analogs
CA2390295A1 (en) A method for chemoprevention of prostate cancer
WO2000047720A3 (en) Pancreatic progenitor cells, methods and uses related thereto
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
AU2274201A (en) Compounds and compositions for delivering active agents
AU2002316811A1 (en) Stable formulation of modified glp-1
CO5170495A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES
CA2294783A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
MXPA05009910A (en) Controlled release system containing saccharose acetate isobutyrate.
PL343018A1 (en) Glucocorticoid-selective anti-inflammatory agents
NO995928L (en) Alpha-1-antitrypsin preparations and their method of preparation
AU2251901A (en) Methods and compounds for inhibiting MRP1
WO1998051663A3 (en) 3-epi compounds of vitamin d3 and uses thereof
AU8910698A (en) Alkali metal hybrid spin-exchange optical pumping
AU1345899A (en) Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
GB0227655D0 (en) Use
AU2001293707A1 (en) Anti-inflammatory medicament
GB9907571D0 (en) Compounds
AU3258097A (en) Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process
AU6186499A (en) Agents for the immunotherapy of tumoral diseases
AU2002359635A1 (en) Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
AU3774097A (en) Intermediates for the preparation of 2-imidazoline-5-ones
HUP0300185A2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins